Your browser doesn't support javascript.
loading
Relationships of Cognitive Measures with Cerebrospinal Fluid but Not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals.
Bonomi, Samuele; Lu, Ruijin; Schindler, Suzanne E; Bui, Quoc; Lah, James J; Wolk, David; Gleason, Carey E; Sperling, Reisa; Roberson, Erik D; Levey, Allan I; Shaw, Leslie; Van Hulle, Carol; Benzinger, Tammie; Adams, Morgann; Manzanares, Cecelia; Qiu, Deqiang; Hassenstab, Jason; Moulder, Krista L; Balls-Berry, Joyce E; Johnson, Keith; Johnson, Sterling C; Murchison, Charles F; Luo, Jingqin; Gremminger, Emily; Agboola, Folasade; Grant, Elizabeth A; Hornbeck, Russ; Massoumzadeh, Parinaz; Keefe, Sarah; Dierker, Donna; Gray, Julia; Henson, Rachel L; Streitz, Marissa; Mechanic-Hamilton, Dawn; Morris, John C; Xiong, Chengjie.
Afiliação
  • Bonomi S; Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Lu R; Division of Biostatistics, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Schindler SE; Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Bui Q; Knight Alzheimer Disease Research Center, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Lah JJ; Division of Biostatistics, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Wolk D; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
  • Gleason CE; Goizueta Alzheimer's Disease Research Center, Emory University, Atlanta, GA, USA.
  • Sperling R; Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Roberson ED; Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Levey AI; Wisconsin Alzheimer's Disease Research Center, Madison, WI, USA.
  • Shaw L; Geriatric Research, Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
  • Van Hulle C; Department of Neurology, Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Benzinger T; Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Adams M; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
  • Manzanares C; Goizueta Alzheimer's Disease Research Center, Emory University, Atlanta, GA, USA.
  • Qiu D; Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Hassenstab J; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Moulder KL; Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Balls-Berry JE; Wisconsin Alzheimer's Disease Research Center, Madison, WI, USA.
  • Johnson K; Knight Alzheimer Disease Research Center, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Johnson SC; Mallinckrodt Institute of Radiology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Murchison CF; Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Luo J; Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
  • Gremminger E; Goizueta Alzheimer's Disease Research Center, Emory University, Atlanta, GA, USA.
  • Agboola F; Goizueta Alzheimer's Disease Research Center, Emory University, Atlanta, GA, USA.
  • Grant EA; Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Hornbeck R; Knight Alzheimer Disease Research Center, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Massoumzadeh P; Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Keefe S; Knight Alzheimer Disease Research Center, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Dierker D; Department of Neurology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Gray J; Knight Alzheimer Disease Research Center, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
  • Henson RL; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Streitz M; Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Mechanic-Hamilton D; Wisconsin Alzheimer's Disease Research Center, Madison, WI, USA.
  • Morris JC; Geriatric Research, Education and Clinical Center, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
  • Xiong C; Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Ann Neurol ; 95(3): 495-506, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38038976
OBJECTIVE: Biomarkers of Alzheimer disease vary between groups of self-identified Black and White individuals in some studies. This study examined whether the relationships between biomarkers or between biomarkers and cognitive measures varied by racialized groups. METHODS: Cerebrospinal fluid (CSF), amyloid positron emission tomography (PET), and magnetic resonance imaging measures were harmonized across four studies of memory and aging. Spearman correlations between biomarkers and between biomarkers and cognitive measures were calculated within each racialized group, then compared between groups by standard normal tests after Fisher's Z-transformations. RESULTS: The harmonized dataset included at least one biomarker measurement from 495 Black and 2,600 White participants. The mean age was similar between racialized groups. However, Black participants were less likely to have cognitive impairment (28% vs 36%) and had less abnormality of some CSF biomarkers including CSF Aß42/40, total tau, p-tau181, and neurofilament light. CSF Aß42/40 was negatively correlated with total tau and p-tau181 in both groups, but at a smaller magnitude in Black individuals. CSF Aß42/40, total tau, and p-tau181 had weaker correlations with cognitive measures, especially episodic memory, in Black than White participants. Correlations of amyloid measures between CSF (Aß42/40, Aß42) and PET imaging were also weaker in Black than White participants. Importantly, no differences based on race were found in correlations between different imaging biomarkers, or in correlations between imaging biomarkers and cognitive measures. INTERPRETATION: Relationships between CSF biomarkers but not imaging biomarkers varied by racialized groups. Imaging biomarkers performed more consistently across racialized groups in associations with cognitive measures. ANN NEUROL 2024;95:495-506.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cognição / Doença de Alzheimer / Disfunção Cognitiva Limite: Humans Idioma: En Revista: Ann Neurol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cognição / Doença de Alzheimer / Disfunção Cognitiva Limite: Humans Idioma: En Revista: Ann Neurol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos